## JAZZ: Jazz Pharmaceuticals plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.7% below STRENGTH zone (3.0-6.0%); PEG 3.97 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($150.96)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Kennedy Capital Management LLC Buys Shares of 10,367 Jazz Pharmaceuticals PLC $JAZZ**
- Source: MarketBeat | 20251208T120920 | Somewhat-Bullish | Relevance: 99%
-  Kennedy Capital Management LLC has acquired 10,367 shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in Q2, valued at approximately $1.1 million. Despite significant insider selling totaling $21.57 million in the last quarter, institutions and hedge funds collectively hold 89.14% of the stock. Analysts currently rate Jazz Pharmaceuticals as a "Moderate Buy" with a consensus price target of $195.67.

**2. Schroder Investment Management Group Acquires 8,444 Shares of Jazz Pharmaceuticals PLC $JAZZ**
- Source: MarketBeat | 20251207T101259 | Somewhat-Bullish | Relevance: 98%
- Schroder Investment Management Group significantly increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, acquiring an additional 8,444 shares to bring its total holdings to 17,816 shares valued at approximately $1.891 million. This move comes as institutional investors actively trade the stock, while company insiders have recently been net sellers. Wall Street analysts currently maintain a consensus "Moderate Buy" rating for Jazz Pharmaceuticals, with an average price target of $195.67.

**3. Do New Epidiolex Real‑World Data Reframe Jazz Pharmaceuticals' (JAZZ) Neurology Growth Ambitions?**
- Source: Simply Wall Street | 20251207T041259 | Somewhat-Bullish | Relevance: 97%
- Jazz Pharmaceuticals presented new real-world and Phase 3b/4 data for its epilepsy drug Epidiolex at the American Epilepsy Society 2025 Annual Meeting, showcasing benefits beyond seizure control. While these findings strengthen the Epidiolex franchise, the company's broader investment narrative still hinges on newer neuroscience and oncology assets, such as Ziihera, to offset challenges from its legacy sleep franchise and high debt. Investors should consider these developments within the context of Jazz Pharmaceuticals' overall growth strategy and looming patent expirations.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | UBS | $188 | $163 | +15% |
| 2025-11-18 | Wells Fargo | $235 | $170 | +38% |
| 2025-11-18 | Baird | $209 | $160 | +31% |
| 2025-11-18 | B of A Securiti | $247 | $230 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | UBS | down | Neutral |
| 2025-11-18 | Wells Fargo | main | Overweight |
| 2025-11-18 | Baird | main | Outperform |
| 2025-11-18 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.71M) |
| Sells | 10 ($6.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.7% (-3.0%)
- Blackrock Inc.: 9.2% (-4.2%)
- JPMORGAN CHASE & CO: 6.2% (+117.0%)
- Dimensional Fund Adv: 4.7% (+11.8%)
- Capital World Invest: 4.2% (+0.4%)

### Key Risks

1. Insider selling cluster: $6.4M in recent transactions.
2. Valuation stretched: PEG 4.0x requires aggressive growth execution.
3. Elevated short interest (9.2%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 5 raises (avg +20%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.97 signals overvaluation risk, limited margin of safety. Forward P/E 7.1x attractive for 180% earnings growth. Analyst sentiment positive (5 raises, avg +20%). Insider selling cluster ($6.4M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.9B |
| Beta | 0.31 |
| 52W Range | $95.49 - $182.99 |
| Short Interest | 9.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.97 |
| Forward P/E | 7.1 |
| Current P/E | 20.0 |
| YoY Growth | 180.0% |
| EPS Direction | RISING |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 8.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.29x) but short-term weakness (below SMA20). MACD histogram bearish (-1.96), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.71% (CS: 6) | Weak |
| RSI_14 | 51.9 | Neutral |
| MACD Histogram | -1.96 | Bearish |
| vs SMA20 | 0.976x | Below |
| vs SMA50 | 1.094x | Above |
| vs SMA200 | 1.292x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $162.26
- **Stop Loss:** $150.96 (7.0% risk)
- **Target:** $173.56 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 26
- **Position Value:** $4,218.76
- **Portfolio %:** 4.22%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-24 (Est: $6.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.85 | $8.13 | +39.0% |
| 2025Q2 | $-6.25 | $-8.25 | -32.1% |
| 2025Q1 | $4.66 | $1.68 | -63.9% |
| 2024Q4 | $5.81 | $6.60 | +13.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*